Fumitake Kai
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
-
- Cancer Genomics and Diagnostics
Papers in
- Oncology 9
- Cancer-related Molecular Pathways 7
-
- RNA modifications and cancer 3
- Epigenetics and DNA Methylation 2
- Ubiquitin and proteasome pathways 2
- Glycosylation and Glycoproteins Research 1
- Co-authors
- Kazushi Inoue (9 shared papers)Robert D. Kendig (8 shared papers)Dejan Maglic (7 shared papers)Pankaj Taneja (5 shared papers)Takayuki Sugiyama (9 shared papers)Donna P. Frazier (4 shared papers)Sinan Zhu (1 shared paper)Mark C. Willingham (3 shared papers)
- Journals
- Japanese Journal of Clinical Oncology (4 papers)Cancer Research (3 papers)Oncogene (1 paper)Expert Review of Molecular Diagnostics (1 paper)Cancer Investigation (1 paper)
- Partner nations
- JapanUnited States
In The Last Decade
Fumitake Kai
18 papers receiving 430 citations
Peers
Comparison fields: 5 of 57
- Oncology 205
- Cancer Research 77
- Pulmonary and Respiratory Medicine 109
- Immunology and Allergy 17
- Molecular Biology 193
Countries citing papers authored by Fumitake Kai
This map shows the geographic impact of Fumitake Kai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumitake Kai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumitake Kai more than expected).
Fields of papers citing papers by Fumitake Kai
This network shows the impact of papers produced by Fumitake Kai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumitake Kai. The network helps show where Fumitake Kai may publish in the future.
Co-authors
The 25 scholars most cited alongside Fumitake Kai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 124 | |
| 2 | 2015 | 69 | |
| 3 | 2009 | 57 | |
| 4 | 2012 | 34 | |
| 5 | 2009 | 33 | |
| 6 | 2010 | 33 | |
| 7 | 2012 | 30 | |
| 8 | 2006 | 20 | |
| 9 | 2011 | 12 | |
| 10 | 2017 | 9 | |
| 11 | 2009 | 3 | |
| 12 | 2013 | 3 | |
| 13 | 2013 | 3 | |
| 14 | 2020 | 2 | |
| 15 | 2009 | 2 | |
| 16 | 2013 | 2 | |
| 17 | 2011 | 1 | |
| 18 | 2010 | 1 | |
| 19 | 2011 | 0 |
About Fumitake Kai
Fumitake Kai is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 19 papers that have together received 438 indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (7 papers), Renal cell carcinoma treatment (5 papers), Cancer Genomics and Diagnostics (3 papers), RNA modifications and cancer (3 papers), Epigenetics and DNA Methylation (2 papers), Ubiquitin and proteasome pathways (2 papers), Adrenal and Paraganglionic Tumors (2 papers) and Glycosylation and Glycoproteins Research (1 paper). The work is most often cited by research in Oncology (205 citations), Cancer Research (77 citations), Pulmonary and Respiratory Medicine (109 citations), Immunology and Allergy (17 citations) and Molecular Biology (193 citations). Fumitake Kai has collaborated with scholars based in Japan and United States. Frequent co-authors include Kazushi Inoue, Robert D. Kendig, Dejan Maglic, Pankaj Taneja, Takayuki Sugiyama, Donna P. Frazier, Sinan Zhu, Mark C. Willingham, Hiroshi Furuse and Elizabeth A. Fry. Their work appears in journals such as Japanese Journal of Clinical Oncology, Cancer Research, Oncogene, Expert Review of Molecular Diagnostics and Cancer Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.